Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity
Stavros P. Papadakos, Nikolaos Dedes, Elias Kouroumalis, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3150-3150
Open Access | Times Cited: 19

Showing 19 citing articles:

Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy
Elias Kouroumalis, Ioannis Tsomidis, Argyro Voumvouraki
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1166-1166
Open Access | Times Cited: 19
The Emerging Role of Metformin in the Treatment of Hepatocellular Carcinoma: Is There Any Value in Repurposing Metformin for HCC Immunotherapy?
Stavros P. Papadakos, Daniele Ferraro, Gabriele Carbone, et al.
Cancers (2023) Vol. 15, Iss. 12, pp. 3161-3161
Open Access | Times Cited: 19
γδ T Cells: A Game Changer in the Future of Hepatocellular Carcinoma Immunotherapy
Stavros P. Papadakos, Konstantinos Arvanitakis, Ioanna Ε. Stergiou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1381-1381
Open Access | Times Cited: 6
Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome in systemic lupus erythematosus
Xiaoxiao Wu, Junhao Yang, Juanjie Wu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 172, pp. 116261-116261
Open Access | Times Cited: 6
Exploring the JAK/STAT Signaling Pathway in Hepatocellular Carcinoma: Unraveling Signaling Complexity and Therapeutic Implications
Hyun-Jung Park, S.-H. Lee, Jaehun Lee, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13764-13764
Open Access | Times Cited: 19
NLRP3 inflammasome in hepatic diseases: A pharmacological target
Erika Ramos‐Tovar, Pablo Muriel
Biochemical Pharmacology (2023) Vol. 217, pp. 115861-115861
Closed Access | Times Cited: 17
Unveiling the Yin-Yang Balance of M1 and M2 Macrophages in Hepatocellular Carcinoma: Role of Exosomes in Tumor Microenvironment and Immune Modulation
Stavros P. Papadakos, Nikolaos Machairas, Ioanna Ε. Stergiou, et al.
Cells (2023) Vol. 12, Iss. 16, pp. 2036-2036
Open Access | Times Cited: 11
The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment
Stavros P. Papadakos, Nikolaos Dedes, Nikolina Gkolemi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 3015-3015
Open Access | Times Cited: 10
Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications
Stavros P. Papadakos, Ioanna Ε. Stergiou, Nikolina Gkolemi, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3434-3434
Open Access | Times Cited: 9
Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches
Konstantinos Arvanitakis, Stavros P. Papadakos, Vasileios Lekakis, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14704-14704
Open Access | Times Cited: 8
Ropivacaine synergizes with sorafenib to induce apoptosis of hepatocellular carcinoma cells via the IL‐6/STAT3 pathway
Wenting Wang, Hongyun Lin, Desheng Liu, et al.
Cancer Science (2024) Vol. 115, Iss. 9, pp. 2923-2930
Open Access | Times Cited: 2
NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies
Pengfei Chen, Xia Li
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
NLRP3 inflammasome activation By 17β-estradiol is a potential therapeutic target in hepatocellular carcinoma treatment
Sara F. Awwad, Raymonde Assaf, Ahmed A. Emam, et al.
Medical Oncology (2023) Vol. 40, Iss. 3
Open Access | Times Cited: 7
Interplay of Extracellular Vesicles and TLR4 Signaling in Hepatocellular Carcinoma Pathophysiology and Therapeutics
Stavros P. Papadakos, Konstantinos Arvanitakis, Ioanna Ε. Stergiou, et al.
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2460-2460
Open Access | Times Cited: 5
Effect of abdominal aortic calcification on long‐term outcomes after the first liver resection in very old patients with hepatocellular carcinoma
Yosuke Namba, Masahiro Ohira, Yuki Imaoka, et al.
Annals of Gastroenterological Surgery (2024) Vol. 9, Iss. 1, pp. 169-177
Open Access
Exploring the Role of GITR/GITRL Signaling: From Liver Disease to Hepatocellular Carcinoma
Stavros P. Papadakos, Elena Chatzikalil, Georgios Vakadaris, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2609-2609
Open Access
Mitochondrial ROS, a trigger for mitochondrial dysfunction and inflammasome activation and a therapeutic target in liver diseases
Hala Saeed Jaara, Sandra Torres
(2024) Vol. 3, Iss. 6, pp. 474-503
Open Access
Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging
Brian J. Engel, Vincenzo Paolillo, Md Nasir Uddin, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3787-3787
Open Access | Times Cited: 1
Pathology of Urologic Cancers
Giovanni Tossetta, Roberta Mazzucchelli
Cancers (2022) Vol. 14, Iss. 15, pp. 3751-3751
Open Access | Times Cited: 1
Page 1

Scroll to top